Microbial consortia and IP in Europe
Protecting new and inventive innovations in this increasingly crowded area is essential, explains Ine Vanderleyden of Mewburn Ellis.
The increasing relevance of ‘technical character’
Two decisions from the European Patent Office offer important guidance for healthcare inventions that use computers, says Rosie McDowell of EIP.
CMA costs case improves access to justice
The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows.
WTO's COVID deal: more vaccine ‘enabler’ than IP waiver?
The COVID-19 IP agreement promises to enable developing countries more autonomy to produce and distribute vaccines, but it has attracted many critics, finds Sarah Speight.
Gilenya injunction bid: big pharma takeaways
The England and Wales Patent Court affirmed its power to grant injunctions for pre-grant patents—but not for Novartis, explains Azadeh Vahdat of EIP.
Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox
Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.
Gene-editing bill: encouraging innovation or adding complexity?
UK legislation to streamline gene-editing technology research is promising for innovation, but presents potential complications for IP, finds Sarah Speight.
Neurim, Flynn discover that time is not on their side
The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.
South Africa: homeopathy case clarifies ‘medicine’ definition
South Africa’s Supreme Court has declared regulations on complementary medicines invalid, explain Kareema Shaik and Jenny Pienaar of Adams & Adams.
Predicting the unpredictable during pregnancy
A pressing need for more non-invasive prenatal tests is leading to increasing IP activity and commercial interest, say Fran Salisbury and Alice Jefferies of Mewburn Ellis.
